We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pacira BioSciences Inc | NASDAQ:PCRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.74 | -2.40% | 30.08 | 28.32 | 31.70 | 31.60 | 30.01 | 31.18 | 684,354 | 01:00:00 |
“Mark’s deep clinical expertise along with his proven executive track record of driving medical innovation will be an exceptional resource to Pacira as we advance our corporate mission to provide non-opioid pain control to as many postsurgical patients as appropriate,” said Dave Stack, chairman and chief executive officer of Pacira. “Mark’s leadership at Trinity Health has given him unique and relevant insights into refining patient care, especially those at risk for opioid dependence and addiction. We welcome Mark and look forward to his contributions to the Pacira Board of Directors.”
Prior to his executive leadership position at Trinity Health, Dr. Froimson was president and chief executive officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions including president of the professional staff, vice chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees.
Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University. He completed his general surgical and orthopedic training at the University of California, Los Angeles and Columbia-Presbyterian Medical Center. He completed his fellowship in adult reconstructive surgery at the University Hospitals of Cleveland.
Dr. Froimson’s publications include authoring book chapters, abstracts and articles in scientific journals, such as the Journal of Arthroplasty, the Journal of Bone and Joint Surgery, the Cleveland Clinic Journal of Medicine and the American Journal of Orthopedics. In addition, he serves in an editorial capacity for numerous scientific publications.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Coyne Public Relations Alyssa Schneider, (973) 588-2270 aschneider@coynepr.com
1 Year Pacira BioSciences Chart |
1 Month Pacira BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions